BioAlliance Pharma in 40M-euro fund raising
Paris, France-based BioAlliance Pharma, which is focused on the development and commercialization of therapeutics targeting drug resistance in cancer, HIV, and opportunistic infections, says that it has raised funds by means of a private placement, using the authorization granted by the extraordinary shareholder meeting of April 24. The gross proceeds of the share capital increase amounts to 40.0 million euros ($55.3 million).
The share capital increase, led by Bryan, Garnier & Co as manager and bookrunner, was reserved for 32 international institutional qualified investors (companies or investment funds) investing in the pharmaceutical/biotechnology sector.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze